Goldman Sachs Group Inc Red Hill Biopharma Ltd. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	SELL	$0.14 - $695.9 $2,939 - $14.6 Million	-20,998 Reduced 54.04%	17,861 $2,000
Q4 2022 Feb 13, 2023	SELL	$0.14 - $695.9 $2,939 - $14.6 Million	-20,998 Reduced 54.04%	17,861 $2,000
Q3 2022 May 14, 2024	BUY	$0.5 - $523.8 $1,269 - $1.33 Million	2,538 Added 6.99%	38,859 $20,000
Q3 2022 Nov 10, 2022	BUY	$0.5 - $523.8 $1,269 - $1.33 Million	2,538 Added 6.99%	38,859 $0
Q2 2022 May 14, 2024	BUY	$0.63 - $2.58 $22,882 - $93,708	36,321 New	36,321 $32,000
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.58 $401 - $1,643	-637 Reduced 1.72%	36,321 $32,000
Q1 2022 May 16, 2022	SELL	$1.65 - $3.12 $11,863 - $22,432	-7,190 Reduced 16.29%	36,958 $93,000
Q4 2021 Feb 14, 2022	SELL	$2.31 - $5.85 $74,428 - $188,487	-32,220 Reduced 42.19%	44,148 $114,000
Q3 2021 Nov 10, 2021	BUY	$4.55 - $10.36 $347,474 - $791,172	76,368 New	76,368 $350,000

40.4K

Ticker RDHL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 63,823,500
Market Cap $465M
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.